spacer
home > ebr > Spring 2007
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2007

At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
bullet
BioFinance and Management
With the IM market now thought to be worth £1 billion a year, The Life Science Love Affair with Interim Management is elucidated by Perry Evans of RSA  
view
download pdf
It has now been several months since the implementation of a European regulation designed to encourage the development of medicines for children. In Child’s Play, Dr Duncan Curley of McDermott Will & Emery UK LLP reviews measures taken to put the new legislation into action  
view
download pdf
bullet
BioBusiness Development
Business strategies that rely on later generation advances must be careful not to fall foul of the law of obviousness. In her in-depth article, Jen Zarutskie at Foley Hoag examines the Patently Obvious  
view
download pdf
One person’s junk is another person’s treasure: in Biotech Bootsale, Michael O’Sullivan and Richard Brown at Plexus Ventures apply this principle to non-strategic assets, finding that better value is often realised by selling to the highest bidder  
view
download pdf
As new technologies emerge from universities into the business world, many academics are finding highly lucrative returns. Nicos Nicolaou at the Tanaka Business School, Imperial College London, helps pave the way for A Spinning Streak: A Four-Dimensional Perspective on University Spinouts  
view
download pdf
bullet
BioResearch and Innovation
Expectations are high for a cross-industry boom in microfluidics. Géraldine Andrieux-Gustin at Yole Développement provides a closer look at the implications for life sciences, in Microfluidics: Just a Drop in the Ocean?  
view
download pdf
In Cells, Gels and Alginates, Are Kristiansen, Jan Egil Melvik and Therese Andersen at NovaMatrix tackle the technological challenges relating to alginate purity, biocompatibility and formulations  
view
download pdf
Our ageing population is placing demands on specialist bone tissue companies for new therapeutic tools. Ronan Le Bot at Atlantic Bone Screen SAS takes a look at a few Skeletons in the Closet  
view
download pdf
Antibody Conjugates Promise to Deliver – site specific delivery is one of many applications for which antibodies are proving useful. Shane Olwill, Richard Buick and Christopher Scott at Fusion Antibodies outline the expectations  
view
download pdf
Kate Rowley at Nexxus tracks the myriad benefits of Systems and Networks, with reference not only to biological systems but also to the wider bioscience business community  
view
download pdf
Existing therapies for the treatment of rheumatoid arthritis can be expensive; Dr Hans Christian Thørgersen of Borean Pharma finds Rheum for Improvement  
view
download pdf
bullet
Discovery Technology
High attrition rates lead to costly failures; in Bound but not Gagged, Biacore’s Gary Franklin investigates how binding kinetics are unlocking more successful compounds  
view
download pdf
As cheap, accurate biosensors become more widespread, Mark Rodgers and Paul Millner at the University of Leeds consider the fashion for biosensors, in Biosensors: Rapid, Preparation-Free Measurement  
view
download pdf
bullet
BioDevelopment and Regulatory
Michael Rosenberg of Health Decisions discusses a strategy that allows researchers to alter clinical studies based on analysis of incomplete results, in Adaptive Research: New Leverage for Biotech  
view
download pdf
In Life after Death, Ann-Christin Malmborg Hager and Christina Furebring at Alligator Bioscience AB and Philippe Stas at AlgoNomics look at the growing trend for reinstating abandoned clinical trials  
view
download pdf
Adjuvants are changing our understanding of carrier system technology for vaccine delivery. In Natural and Synthetic Additives, Vincent W Bramwell and Yvonne Perrie at the University of Aston illuminate recent developments  
view
download pdf
Tanja Beilke, Oliver Halbig and Andreas Richter at NewLab BioQuality AG avoid the potential dangers of contaminants, in Without a Trace  
view
download pdf
With TeGenero still very much in the public consciousness, Anthony Warnock-Smith at Morgan Lewis lays down The Legal Implications of Phase I Clinical Trials  
view
download pdf
bullet
BioFormulation and Manufacturing
In Environmental Exposure, Brigitte van Noorloos at NOTOX provides guidance on avoiding biopharma’s potentially harmful environmental impact  
view
download pdf
Once a patent has been granted, the profit clock starts ticking. Dale McQueen at Lanner Group discusses the predictions made possible by simulation, in Against the Clock  
view
download pdf
In Pushing Biobank Standardisation, Dr Achim Quandt of QIAGEN GmbH makes the case for closer collaboration between biobanks and better systems for tissue management  
view
download pdf
Moving on Up: The Cultivation of Upstream Strategies. Cell line production can always be made more efficient, both in terms of speed and cost; Andreas Herrmann at Celonic suggests one useful approach  
view
download pdf
Botulinum neurotoxins can be lethal even in small doses, and yet they are also an approved therapy for a variety of debilitating conditions. John A Chaddock and Keith Foster at Syntaxin Ltd resolve the paradox of a Novel Therapeutics from a Toxin  
view
download pdf
bullet
BioRegional
In Ontario’s Biopharma Boom, Bill Mantel at the Ontario Ministry of Research characterises the region’s thriving biopharmaceutical sector  
view
download pdf
Géraldine Filippi at the Invest in France Agency, London, evaluates recent outlays from abroad, in French Connection: A Record for Foreign Investment  
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th


More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement